ADAM21

Across TCGA pan-cancer cohorts, ADAM21 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated ADAM21 data layer compared with 22 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ADAM21 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ADAM21 expression acts as an unfavorable survival marker, although some lineages such as LUSC show a favorable association.

LUAD, THCA, and BRCA are the cancer types where ADAM21 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.190	0.791	<.001	34	view →
THCA	DFS	Median	All	0.027	0.945	<.001	24	view →
BRCA	OS	Median	All	0.107	0.578	.005	12	view →
BLCA	OS	Median	III,IV	0.215	0.656	.003	9	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	DFS	Median	IV	0.040	0.454	.028	6	view →
LUSC	OS	Median	All	1.000	0.666	.013	5	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

ADAM21–LUAD (OS)

Open the LUAD breakdown →